Symptoms Archives - Cholestasis Unveiled: Navigating Rare Liver Disorders

Evolving therapeutic approaches in late-onset genetic cholestasis

Carola Dröge and Verena Keitel-Anselmino discuss IBAT inhibitor therapy in adults with hereditary BSEP-deficiency at EASL 2026.

Observational data show IBAT inhibitor promise for pruritus in late-onset PFIC and ICP

Real-world data show promise for IBAT inhibitor use in adults with late-onset PFIC and women with ICP.

Intrahepatic cholestasis of pregnancy recurs in 4 in 10 pregnancies

Researchers evaluate the incidence of intrahepatic cholestasis of pregnancy recurrence and identify potential predictors.

Case series suggests IBAT inhibitor benefits in adults with hereditary BSEP deficiency

Clinical data suggest comparable IBAT inhibitor response for adults with hereditary BSEP deficiency as seen in pediatric trials.

Researchers call for ICP to be included in hepatobiliary risk stratification

Intrahepatic cholestasis of pregnancy significantly increases the risk for developing hepatobiliary morbidity.

Genetic variants explain substantial proportion of undiagnosed cholestasis and hepatitis

Study findings support early genetic testing for unexplained idiopathic chronic cholestasis and hepatitis of unknown origin.

AASLD 2025 Reflections: Key takeaways in primary sclerosing cholangitis

Dr Marlyn Mayo and Dr Andreas Kremer share key insights on primary sclerosing cholangitis from AASLD The Liver Meeting 2025, and explore the latest in therapeutic developments and symptomatology.

AASLD 2025 Reflections: Key takeaways in late-onset genetic cholestasis

Dr Silvia Vilarinho and Dr Deepak Joshi share the highlights from AASLD The Liver Meeting 2025, with an emphasis on late-onset genetic cholestasis, and offer quick insights into new data on the growing utility of genetic testing and expanding therapeutic implications.

AASLD 2025 Reflections: Key takeaways in primary biliary cholangitis

Dr Andreas Kremer and Dr Marlyn Mayo highlight key advances in primary biliary cholangitis from AASLD The Liver Meeting 2025, and provide quick insights into the latest data on next-generation therapies.

Seladelpar improves wellbeing and lowers itch impact

Marlyn Mayo reviews RESPONSE analyses on seladelpar symptom effects in PBC.

Survey reveals limitations to pruritus assessment in PSC

Marlyn Mayo discusses findings on physician attitudes to managing pruritus in PSC.

Ongoing seladelpar treatment continues to benefit PBC patients

Giving seladelpar beyond 12 months offers primary biliary cholangitis patients improvements in pruritus and biochemical markers, show ongoing analyses.

Maralixibat offers clinically meaningful pruritus reductions in PSC

A real-world analysis of PSC patients given maralixibat suggests it offers meaningful improvements in pruritus.

Genetic etiology may explain majority of adult-onset cholestatic disorders

Most cases of unexplained cholestasis in adults have an identifiable underlying genetic cause.

Digital mind–body intervention helps symptom management in liver disease

A mind–body intervention accessed online may help patients with liver disease better manage their symptoms.

Volixibat improves fatigue and sleep in PBC alongside pruritus

An analysis of trial data indicates that, alongside reducing pruritus, volixibat helps normalize fatigue and sleep in PBC patients.

Novel panel identifies variants in unexplained cholestatic cases

A large US gene panel has helped to elucidate the underlying genetic basis of unexplained cholestasis.

Gene mutations linked to adult cholestasis

Mitchell Shiffman discusses the value of genetic testing in adults with undefined cholestasis.

Sustained responses to elafibranor in PSC

Mitchell Shiffman comments on ELMWOOD findings for elafibranor in PSC.

Long-term elafibranor therapy improves PBC outcomes

ELATIVE open-label extension trial findings support long-term elafibranor treatment in patients with PBC.

Distressing PSC symptoms fit profiles that could guide treatment

US researchers have found that the numerous and potentially distressing symptoms of PSC fit into four clear profiles.

Predictive model with standard clinical parameters differentiates PSC and SSC

Natural language programming could help identify which adults with cholestasis have late-onset progressive familial intrahepatic cholestasis.

Pharmacodynamic findings support linerixibat pruritus benefits in patients with PBC

Andreas Kremer explains post-hoc analysis findings from the phase 3 GLISTEN trial showing an effect of linerixibat on biomarkers and mediators of pruritus in patients with PBC.

ELATIVE: Sustained elafibranor benefit and biomarker potential

Mark Swain on 3-year elafibranor benefits, proteomics in PBC.

Seladelpar cholestasis benefits extend long term

Discussing the ASSURE findings for seladelpar in PBC with Daniel Pratt.

NLP medical review may help identify adults with undiagnosed PFIC

Natural language programming could help identify which adults with cholestasis have late-onset progressive familial intrahepatic cholestasis.

IBAT inhibitors may improve post-liver transplant pruritus

Treatment-refractory pruritus following liver transplant may be successfully treated with IBAT inhibitors, suggests a US case series.

Responses to elafibranor in primary sclerosing cholangitis maintained after initial treatment

An open-label trial extension showed that the PPAR agonist elafibranor maintained efficacy, and former placebo patients saw improvements.

Contraceptives linked to unique cholestatic phenotype

Raj Vuppalanchi reports findings characterizing the phenotype of women with hormonal contraceptive-associated drug-induced liver injury.

Elafibranor improves symptom burden, unaffected by BMI

Andreas Kremer discusses post-hoc analyses from the ELATIVE trial showing independent improvement in patient-reported outcomes with elafibranor for patients with PBC and efficacy irrespective of BMI.

Countdown to AASLD 2025: A preview with Marlyn Mayo and Andreas Kremer

Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.

Countdown to AASLD 2025: A preview with Marlyn Mayo and Andreas Kremer

IBAT inhibitor case studies point to adult intrahepatic cholestasis benefits

Ileal bile acid transporter inhibitors help treat adults with drug-induced or pregnancy-related intrahepatic cholestasis

Diagnosing and managing late-onset genetic cholestasis: a clinical pathway tool

A practical algorithm tool to help you navigate the different clinical presentations, reach an accurate diagnosis, and take optimal first management steps.

EASL guidelines offer ‘framework’ for intrahepatic cholestasis of pregnancy care

Research confirms that the EASL guidelines aid risk stratification for intrahepatic cholestasis of pregnancy.

Pathogenic variants common in adult-onset cholestasis patients

Research shows the utility of genetic testing for patients with adult-onset cholestatic disease.

ABCB4 variant genotype–phenotype relationship in cholestasis elucidated

Research sheds light on the varying impact of ABCB4 gene variants in intrahepatic cholestasis of pregnancy and other adult-onset forms of cholestasis.

Odevixibat update for adult PFIC, older Alagille syndrome patients

Updated results for adult participants of the PEDFIC2 trial and older children taking part in the ASSERT-EXT study.

Genetic analysis aids diagnosis for atypical PFIC presentation

Case studies demonstrate the utility of genetic analysis and whole-exome sequencing for the diagnosis of progressive familial intrahepatic cholestasis in patients with nonspecific liver disease.

About late-onset genetic cholestasis

Richard Thompson provides a concise overview of late-onset genetic cholestasis, including the pathophysiology and genetics behind the various phenotypes that can present, in this short, animated video.

About late-onset genetic cholestasis

Unmet needs in late-onset genetic cholestasis: an expert discussion

This CME-accredited expert discussion aims to highlight the unmet needs in late-onset genetic cholestasis and provide guidance on the use of genetic testing in the diagnostic workup and initial management steps for the different genotypes, with reference to key trials and updates from The Liver Meeting 2024: American Association for the Study of Liver Diseases (AASLD).

Comprehensive PBC management: innovative and personalized plans to enhance patient outcomes

Led by Emma Culver, this interactive case study follows a 40-year-old woman who is referred to the clinic following profound fatigue, and discusses how management plans can be personalized to best support patient outcomes.

ABCB11 alteration linked to anabolic steroid-induced liver injury susceptibility

Dr Andrew Stolz reports on the relationship between alterations to the ABCB11 gene and the risk of drug-induced liver injury from anabolic steroids.

ABCB11 variants increase susceptibility to anabolic steroid-induced liver injury

Alterations to ABCB11 play a “pivotal role” in the development of drug-induced liver injury from anabolic steroids, US researchers reported at the 2024 AASLD The Liver Meeting in San Diego, California, USA.

Navigating Challenges in PBC Management: Focus on Inadequate Responders and Symptomatic Itching

In this case study module, Marlyn Mayo discusses 3 short patient profiles to illustrate difficult situations when treating patients with PBC including managing inadequate response to initial therapy and symptomatic itching.

Breaking down PBC: a comprehensive guide

Led by Kris Kowdley, this interactive, comprehensive guide to Primary Biliary Cholangitis (PBC) provides details on the pathogenesis, diagnosis, management and latest clinical data for PBC. Click through the sections, or download the PDF to use as a guide in your clinic.

Breaking down PBC: a comprehensive guide

Interactive, comprehensive guide to Primary Biliary Cholangitis (PBC) providing details on the pathogenesis, diagnosis, management and latest clinical data.

PBC Clinical insights: evaluating therapeutic response and disease management

CME case study for the identification and management of Primary Biliary Cholangitis (PBC) including therapy response and disease management, for a 42 year old with abnormal liver blood test results.

Coping with PBC: treatment challenges and QoL insights

Kris Kowdley meets with patient Sabrina Reeser as they discuss the patient experience of treatment for PBC, including treatment challenges, variability in doctor-patient communication and involvement in clinical trials.

ELATIVE trial shows pruritus benefits with elafibranor in PBC

ELATIVE trial results for pruritus show benefits for both severity and impact on the quality of life of patients with primary biliary cholangitis.

Walking the path of PBC: navigating symptoms and QoL

David Jones meets with patient and patient advocate Mo Christie as they discuss the patient experience for PBC, including the burden of the disease and its impact on quality of life, with special reference to the common, and commonly misunderstood symptom, itch.

Barriers and symptoms burden: the unmet needs in PBC

Drs Marlyn Mayo and Gideon Hirschfield discuss the unmet needs in PBC management, highlighting the significant burden that symptoms pose for patients, the importance of monitoring and a patient-centric management approach offering insights into what might lie ahead in 2024.

Tag: Symptoms